Selective boron drug delivery to brain tumors for boron neutron capture therapy

Advanced Drug Delivery Reviews

Volumn 26, Issue 2-3, 1997, Pages 231-247

  Chen, Wei ^a   Mehta, Samir C ^a,b   Lu, D Robert ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Blood brain barrier; Boron neutron capture therapy; Brain tumors; Malignant glioma; Selective drug delivery

Indexed keywords

BIOCHEMISTRY; BLOOD; BORON; BRAIN; CELLS; MONOCLONAL ANTIBODIES; ONCOLOGY; PROTEINS;

BLOOD BRAIN BARRIER; BORON NEUTRON CAPTURE THERAPY (BNCT);

CONTROLLED DRUG DELIVERY;

BORON DERIVATIVE; IMMUNOLIPOSOME; LIPOSOME; NUCLEOSIDE DERIVATIVE; PORPHYRIN DERIVATIVE;

BLOOD BRAIN BARRIER; BRAIN TUMOR; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; ELECTROPORATION; GLIOBLASTOMA; HUMAN; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS;

EID: 0031558237     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00037-9     Document Type: Review

References (131)

1. P. Paoletti, R. Knerich, D. Adinolfi, G. Butti, S. Pezzotta, Therapy for central nervous system malignant tumors. In: M.A. Gerosa, M.A. Rosenblum. and G. Tridente (Eds.), Brain Tumors: Biopathology and Therapy, Advances in the Biosciences, Vol. 58. Pergamon, Oxford, 1985, pp. 223-235.
2. J. Hildebrand, Current status of chemotherapy of brain tumors, Prog. Exp. Tumor Res. 29 (1985) 152-166.
3. H. Brem, M.S.J. Mahaley, N.A. Vick, Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas, J. Neurosurg. 74 (1991) 441-446.
4. R.C. Florell, D.R. Macdonald, W.D. Irisa, Selective bias, survival, and brachytherapy for glioma, J. Neurosurg. 76 (1992) 179-183.
5. J.T. Godwin, L.E. Farr, W.H. Sweet, J.S. Robertson, Pathological study of eight patients with glioblastoma multiform treated by neutron-capture therapy using boron 10, Cancer 8 (1955) 601-615.
6. A.H. Soloway, R.F. Barth, F. Alam, Boron compounds and boronated antibodies for neutron capture therapy. In: H. Hatanaka (Ed.), Boron Neutron Capture Therapy for Tumors. Nishimura, Niigata, 1986, pp. 47-58.
7. M. Abe, K. Amano, K. Kitamura, M. Ohta, J. Tateishi, H. Hatanaka, Capillary permeability and boron distribution in ethylnitrosourea-induced rat glioma, Neurosurgery 22(1) (1988) 23-31.
8. N.R. Clendenon, R.F. Barth, W.H. Gordon, R. Alam, A.H. Soloway, A.E. Staubus, C.P. Boesel, A.J. Yates, N.C. Noeschverger, R. Gahbauer, R.G. Fairchild, D.N. Slatkin, J. Kalef-Ezra, Boron neutron capture therapy of rat glioma, Neurosurgery 26 (1990) 47-55.
9. H. Hatanaka, Y. Nakagawa, Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy, Int. J. Radiat. Oncol. Biol. Phys. 28(5) (1994) 1061-1066.
10. E.I. Tolpin, G.R. Wellum, F.C. Dohan, P.L. Kornblith, R.G. Zamenhof, Boron neutron capture therapy of cerebral gliomas: II. Utilization of the blood-brain barrier and tumor-specific antigens for the selective concentrations of boron in glioma, Oncology 32 (1975) 223-246.
11. R.F. Barth, A.H. Soloway, R.G. Fairchild, R.M. Brugger, Boron neutron capture therapy for cancer, Cancer 70 (1992) 2995-3007.
12. N.H. Greig, Brain tumors and the blood-tumor barrier. In: E. Neuwelt (Ed.), Implications of the Blood-Brain Barrier and its Manipulation, Vol. 2, Clinical aspects, Plenum Press, New York, 1989, pp. 77-106.
13. V.A. Levin, Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability, J. Med. Chem. 23 (1980) 682-684.
14. W.M. Pardridge, Blood-brain nutrient transport, Fed. Proc. 45 (1986) 2047-2049.
15. T. Terasaki, A. Tsuji, Drug delivery to the brain utilizing blood-brain barrier transport system, J. Control. Release 29 (1994) 163-169.
16. S.C. Mehta, D.R. Lu, Targeted drug delivery for boron neutron capture therapy, Pharm. Res. 13(3) (1996) 344-351.
17. D. Triguero, J.B. Buciak, J. Yang, W.M. Pardridge, Blood-brain barrier transport of cationized immunoglobulin G: Enhanced delivery compared to native protein, Proc. Natl. Acad. Sci. USA 86 (1989) 4761-4765.
18. A.K. Kumagai, J. Eisenberg, W.M. Pardridge, Absorptive-mediated endocytosis of cationized albumin and a β-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport, J. Biol. Chem. 262 (1987) 15214-15219.
19. W.M. Pardridge, D. Triguero, J.L. Buciak, J. Yang, Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector, J. Pharmacol. Exp. Ther. 225 (1990) 893-899.
20. C. Walker, M. Selby, A. Erickson, D. Cataldo, J.P. Valensi, G. Van Nest, Cationic lipid direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway, Proc. Natl. Acad. Sci. USA 89 (1992) 7915-7918.
21. W.A. Jefferies, M.R. Brandon, S.V. Hunt, A.F. Williams, K.C. Gatter, D.Y. Mason, Transferrin receptor on endothelium of brain capillaries, Nature 312 (1984) 162-163.
22. P.M. Friden, L. Walus, G.F. Musso, M.A. Taylor, B. Malfroy, R.M. Starzyk, Antitransferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier, Proc. Natl. Acad. Sci. USA 88 (1991) 4771-4775.
23. W.M. Pardridge, Y. Kang, J.L. Buciak, Transport of human recombinant brain-derived neurotropic factor (BDNF) through the rat blood-brain barrier in vivo using vector-medicated peptide drug delivery, Pharm. Res. 11(5) (1994) 738-746.
24. A.H. Soloway, H. Hatanaka, M.A. Davis, Penetration of brain and brain tumor VII. Tumor-binding sulfhydryl boron compounds, J. Med. Chem. 10 (1967) 714-717.
25. D. Gabel, Present status and perspectives of boron neutron capture therapy, Radiother. Oncol. 30 (1994) 199-205.
26. S.L. Kraft, P.R. Gavin, C.E. DeHann, C.W. Leathers, W.F. Bauer, D.L. Miller, R.V. Dorn III, Borocaptate sodium - a potential boron delivery compound for boron neutron capture therapy evaluated in dogs with spontaneous intracranial tumors, Proc. Natl. Acad. Sci. USA 89 (1992) 11973-11977.
27. M. Abe, K. Kitamura, K. Amano, H. Hatanaka, Boron-10-mercaptoundecahydrododecaborate distribution in rat brain tumors. In H. Hatanaka, (Ed.), Boron Neutron Capture Therapy for Tumors. Nishimura, Niigata, Japan, 1986, pp. 117-124.
28. H. Hatanaka, K. Amano, H. Kanemitsu, I. Ikeuchi, T. Yoshizaki, Boron uptake by human brain tumors and quality control of boron compounds. In H. Hatanaka, (Ed.), Boron Neutron Capture Therapy for Tumors, Nishimura, Niigata, Japan, 1986, pp. 77-106.
29. G. Stragliotto, H. Frankhauser, Biodistribution of boron sulfhydryl for boron neutron capture therapy in patients with intracranial tumors, Neurosurgery 36 (1995) 285-292.
30. 7Li reaction, Radiat. Res. 61 (1975) 304-315.
31. R.A. Rydin, O.L. Deutsch, B.W. Murray, The effect of geometry on capillary wall dose for boron neutron capture therapy, Phys. Med. Biol. 21 (1976) 134-138.
32. R.F. Barth, A.H. Soloway, R.G. Fairchild, Boron neutron capture therapy for cancer, Cancer Res. 50 (1990) 1061-1070.
33. 2 administered to mice, Biochem. Pharmacol. 35(10) (1986) 1771-1776.
34. S.C. Mehta, F.D. Boudinot, D.R. Lu, Pharmacokinetics of sodium mercaptoundecahydrododecaborate (BSH) after intravenous injection in rats, Drug Metabol. Disp. 23(12) (1995) 1368-1371.
35. S.C. Mehta, D.R. Lu, Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits and humans, Biopharm. Drug. Disp. 16 (1995) 735-744.
36. E. Buchar, S. Bednarova, B. Gruner, P. Walder, O. Strouf, I. Janku, Dose-dependent disposition kinetics and tissue accumulation of boron after intravenous injections of sodium mercaptoundecahydrododecaborate in rabbits, Cancer Chemother. Pharmacol. 29 (1992) 450-454.
37. G. Straglitto, H. Fankhauser, Biodistribution of boron sulfhydryl (BSH) in patients with intracranial tumors. In: B. Allen, D. Moore and B. Harrington (Eds.), Progress in Neutron Capture Therapy for Cancer. Plenum, New York, 1992, pp. 551-556.
38. G. Straglitto, D. Schüpbach, P.R. Gavin, H. Fankhauser, Update on biodistribution of borocaptate sodium (BSH) in patients with intracranial tumors. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy, Plenum, New York, 1993, pp. 719-726.
39. K. Amano, Neutron-induced auto radiography of human brain tumors. Presented at the First International Symposium on Neutron Capture Therapy, Brookhaven National Laboratory, New York, 1983.
40. F. Alam, A.H. Soloway, R.F. Barth, Boronation of antibodies with mercaptoundecahydro-closo-dodecaborate (2-) anion for potential use in boron neutron capture therapy, Int. J. Radiat. Applicat. Instr. Part A 38 (1987) 503-506.
41. A.H. Soloway, Boron compounds in cancer therapy. In: H. Sainberg and A.L. McCloskey (Eds.), Progress in Boron Chemistry, Vol. 1. Pergamon, New York, Chap. 4, 1964, pp. 203-234.
42. D. Joel, D. Slatkin, R. Fairchild, P. Micca, M. Nawrocky, Pharmacokinetics and tissue distribution of the sulfhydryl boranes (monomers and dimer) in glioma-bearing rats, Strahlenther. Onkol. 165 (1989) 167-170.
43. R.G. Fairchild, F. Wheeler, D.N. Slatkin, J. Coderre, P. Milla, B. Laster, S.B. Kahl, I. Fand, Recent developments in neutron capture therapy, Strahlenther. Onkol. 165 (1989) 343-347.
44. A.H. Soloway, F. Alam, R.F. Barth, In: R.F. Fairchild and V.P. Bond (Eds.), Workshop on Neutron Capture Therapy. Brookhaven National Laboratory-51994, Upton, 1986, pp. 162-172.
45. 2 in mice. In: R.G. Fairchild, V.P. Bond and A.D. Woodhead (Eds.), Clinical Aspects of Neutron Capture Therapy. Plenum, New York, 1989, pp. 333-351.
46. D.N. Slatkin, P.L. Micca, B.H. Laster, R.G. Fairchild, Distribution of sulfhydryl boranes in mice and rats. In: R.G. Fairchild and V.P. Bond (Eds.), Workshop on Neutron Capture Therapy. Brookhaven National Laboratory-51994, Upton, 1986, pp. 172-176.
47. G.R. Wellum, E.I. Tolpin, A.H. Soloway, A. Kaczmarczyk, Synthesis of m-disulfidobis(undecahydro-closo-dodecaborate) (4-) and a derived free radical, Inorg. Chem. 16 (1977) 2120-2122.
48. J.S. Hill, S.B. Kahl, A.H. Kaye, S.S. Stylli, M. Koo, M.F. Gonzales, N.I. Vardaxis, C.I. Johnson, Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma, Proc. Natl. Acad. Sci. USA 89 (1992) 1785-1789.
49. C.P. Ceberg, A. Brun, S.B. Kahl, M.S. Koo, B.R.R. Persson, L.G. Salford, A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model, J. Neurosurg. 83 (1995) 86-92.
50. R.G. Fairchild, S.B. Kahl, B.H. Laster, J. Kalef-Ezra, E.A. Popenoe, In vitro determination of uptake, retention, distribution, biological efficacy and toxicity of boronated compounds for neutron capture therapy: a comparison of porphyrins with sulfhydryl boron hydrides, Cancer Res. 50(16) (1990) 4860-4865.
51. S.B. Kahl, P. Micca, Chemical and biological studies on boronated tetraphenyl porphyrins. In: H. Hatanaka (Eds.), Boron Neutron Capture Therapy for Tumors. Nishimura, Niigata, Japan, 1986, pp. 61-67.
52. S. Kahl, M. Koo, R. Straubinger, L. Huang, R. Fiel, R. Mazurchuk, J. Alletto, A boronated metalloporphyrin for use in neutron capture therapy and magnetic resonance contrast enhancement of glioma. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy, Plenum, New York, 1993, pp. 301-303.
53. L.R. Huang, R. Sraubinger, S.B. Kahl, M.S. Koo, J.J. Alletto, R. Mazurchuk, R.I. Chau, S.L. Thamer, R.J. Fiel, Boronated metalloporphyrins: a novel approach to the diagnosis and treatment of cancer using contrast-enhanced MR imaging and neutron capture therapy, J. Magn. Reson. Imaging 3(2) (1993) 351-356.
54. 10B-paraborono-phenylalanine HCl to malignant melanoma for thermal neutron capture therapy, Jpn. J. Dermatol. 93 (1983) 773-778.
55. 10B-paraborono-phenylalanine in thermal neutron capture therapy of malignant melanoma: in vivo radiobiological evaluation, J. Invest. Dermatol. 78 (1982) 215-218.
56. 10B-compound, Lancet. II (1989) 388-389.
57. Y. Mishima, M. Ichihashi, S. Hatta, C. Honda, First human clinical trial of melanoma neutron capture, diagnosis and therapy, Strahlenther. Onkol. 165 (1989) 251-254.
58. J.A. Coderre, J.A. Kalef-Ezra, R.G. Fairchild, P.L. Micca, L.E. Reinstein, J.D. Glass, Boron neutron capture therapy of a murine melanoma, Cancer Res. 48 (1988) 6313-6316.
59. J.A. Coderre, J.D. Glass, R.G. Fairchild, P.L. Micca, I. Fand, D. Joel, Selective delivery of boron by the melanin precursor analogue p-boronphenylalanine to tumors other than melanoma, Cancer Res. 50 (1990) 138-141.
60. T. LaHann, C. Sills, G. Hematillake, T. Dymock, G. Daniell, Cardiovascular toxicities associated with intravenous administration of p-boronophenylalanine formulations. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy. Plenum, New York, 1993, pp. 513-517.
61. W.M. Pardridge, Brain drug delivery and blood-brain barrier transport, Drug Del. 3 (1996) 99-115.
62. J.A. Coderre, BNCT for malignant glioma using BPA: radiation biology and treatment planning. In: 6th International Symposium on Neutron Capture Therapy for Cancer, Kobe, Japan, October 32-November 4, 1994, Abstract 6.
63. J.L. Mallesch, D.E. Moore, B.J. Allen, W.H. MacCarthy, R. Jones, W.A. Steining, The pharmacokinetics of p-boronphenylalanine · fructose in human patients with glioma and metastatic melanoma, Int. J. Radiat. Oncol. Biol. Phys. 28(5) (1994) 1183-1188.
64. T.R. LaHann, D.R. Lu, G. Daniell, C. Sills, S.L. Kraft, P.R. Gavin, W.F. Bauer, Bioavailability of intravenous formulations of p-boronphenylalanine in dog and rat. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy. Plenum, New York, 1993, pp. 585-589.
65. K. Yoshino, A. Suzuki, Y. Mori, H. Kakishana, C. Honda, Y Mishima, T. Kobayashi, K. Kanda, Improvement of solubility of p-boronphenylalanine by complex formation with monosaccharides, Strahlenther. Onkcol. 165 (1989) 127.
66. J.A. Coderre, T.M. Button, P.L. Micca, C.D. Fisher, M.M. Nawrocky, H.B. Liu, Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex, Int. J. Radiat. Oncol. Biol. Phys. 30(3) (1994) 643-652.
67. T. LaHann, W.F. Bauer, D.R. Lu, Pharmacokinetics of boronphenylalanine delivered in HP-β-cyclodextrin formulation. In: R.M. Ottenbrite (Ed.), Polymeric Drugs and Drug Delivery Systems, ACS Book series 545, American Chemical Society, Washington, DC, 1994, pp. 66-78.
68. H. Hatanaka, K. Komada, Y. Mishima, K. Okumura, Improved bioavailability of p-boronphenylalanine by cyclodextrin complexation, J. Pharm. Sci. 82(10) (1993) 1054-1057.
69. M. Takagaki, K. Ona, Y. Oda, H. Kikuchi, S. Iwamoto, J. Cai, Y. Yamanoto, Hydroxylforms of p-boronphenylalanine as potential boron carriers on boron neutron capture therapy for malignant brain tumors, Cancer Res. 56 (1996) 2017-2020.
70. V.R. Jarugula, R.F. Schinazi, G. Fulcrand, Y.E. Kattan, D.C. Liotta, F.D. Boudinot, Pharmacokinetics of 5-carboranyl-2′-deoxyuridine in rats, J. Pharm. Sci. 83 (1994) 1697-1699.
71. R.F. Schinazi, W.H. Prusoff, Synthesis of 5-dihydroxyboryl-2′-deoxyuridine and related boron-containing pyrimidines, J. Org. Chem. 50 (1985) 841-847.
72. Y. Yamamoto, T. Seko, H. Nakamura, H. Nemeto, H. Hojo, N. Mukai, Y. Hadhimoto, Synthesis of carborane containing nucleoside bases. Unexpected high cytostatic and cytocidal toxicity towards cancer cells, J. Chem. Soc. Commun. 2 (1992) 157-158.
73. E.A. Neuwelt, P.A. Barnett, D.D. Gigner, E.P. Frenkel, Effects of adrenal cortical steroids and osmotic, blood-brain barrier opening on methotrexate delivery to glioma in the rodent: The factor of the blood-brain barrier, Proc. Natl. Acad. Sci. USA 79 (1982) 4420-4423.
74. E.A. Neuwelt, P.A. Barnett, C.I. McCormick, E.P. Frenkel, J.D. Minna, Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery of cerebrospinal fluid and brain, Neurosurgery 17 (1985) 419-423.
75. K. Tomiwa, F. Hazawa, H. Mikawa, Neurotoxicity of vincristine after the osmotic opening of the blood-brain barrier, Neuropathol. Appl. Neurobiol. 9 (1983) 345-354.
76. E.A. Neuwelt, S.A. Hill, E.P. Frenkel, Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening, Neurosurgery 15 (1984) 362-366.
77. E.A. Neuwelt, S.I. Rapoport, Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors, Fed. Proc. 43 (1984) 214-219.
78. E.A. Neuwelt, D.L. Goldman, S.A. Dahlborg, J. Crossen, F. Ramsey, S. Roman-Goldstein, R. Brazier, B. Dana, Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function, J. Clin. Oncol. 9 (1991) 1580-1590.
79. E.A. Neuwelt, J. Howeison, E.P. Frenkel, H.D. Specht, R. Weigel, C. Buchan, S.A. Hill, Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement of blood-brain barrier modification in glioblastoma, Neurosurgery 19 (1986) 573-583.
80. P.C. Williams, W.D. Henner, S. Roman-Goldstein, S.A. Dahlborg, R.E. Brummet, M. Tableman, B. Dana, E.A. Neuwelt, Toxicity and efficacy of carboplatin and etoposide in conjunction with blood-brain barrier tumor barrier modification in the treatment of intracranial neoplasms, Neurosurgery 37 (1995) 17-28.
81. W. Yang, R.F. Barth, D.E. Carpenter, M.L. Moeschberger, J.H. Goodman, Enhanced delivery of boronphenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption, Neurosurgery 38(5) (1996) 985-992.
82. W. Yang, R.F. Barth, J.H. Rotaru, D.E. Carpenter, D.D. Joel, M.M. Nawrocky, J.H. Goodman, Enhanced survival of F98 glioma-bearing rats following neutron capture therapy with boronphenylalanine and osmotic blood-brain barrier disruption. Congress of Neurological Surgeons 45th Annual Meeting, October 14-19, 1995, pp. 367 (abst).
83. K.L. Black, W.A. King, K. Ikezaki, Selective opening of blood-brain barrier by intracarotid infusion of leukotriene C4, J. Neurosurg. 72 (1990) 912-916.
84. C. Chio, T. Baba, K.L. Black, Selective blood-brain barrier disruption by leukotriene, J. Neurosurg. 77 (1992) 407-410.
85. T. Inamura, K.L. Black, Bradykinin selectively opens blood-tumor barrier in experimental brain tumors, J. Cereb. Blood Flow Metabol. 14 (1994) 862-870.
86. T. Nomura, T. Inamura, K.L. Black, Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors, Brain Res. 659 (1994) 62-66.
87. T. Inamura, T. Nomura, R.T. Bartus, K.L. Black, Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors, J. Neurosurg. 81 (1994) 752-758.
88. L.E. DeBault, γ-glutamyltranspeptidase induction mediated by glial foot process - to endothelium contact in co-culture, Brain Res. 220 (1981) 432-435.
89. K.L. Black, C. Chio, Increased opening of blood-tumor barrier by leukotriene C4 is dependent on size of molecules, Neurol. Res. 14 (1992) 402-404.
90. T. Nagashima, W. Shigin, A. Mizoguchi, M. Arakawa, M. Yamaguchi, N. Tamaki, The effect of leukotriene C4 on the permeability of brain capillary endothelial cell monolayer, J. Pharmacol. Exp. Ther. 271(1) (1994) 55-57.
91. K. Matsukado, T. Inamura, S. Nakano, M. Fukui, R.T. Bartus, K.L. Black, Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7, Neurosurgery 39(1) (1996) 125-134.
92. V. Quagliarello, W.M. Scheld, Bacterial meningitis: pathogenesis, pathophysiology and progress, N. Engl. J. Med. 327 (1992) 864-872.
93. B. Spellerberg, S. Prasad, C. Cabellos, M. Burroughs, P. Cahkl, E. Tuomanen, Penetration of the blood-brain barrier: enhancement of drug delivery and imaging by bacterial glycopeptides, J. Exp. Med. 182 (1995) 1037-1044.
94. C.P. Cerberg, A. Brun, L.M. Mir, B.R.R. Persson, L.G. Salford, Enhanced boron uptake in G2 rat gliomas by electropermeabilization in vivo - a new possibility in boron neutron capture therapy, Anticancer Drug. 5 (1994) 463-466.
95. H. Brem, S. Piantadosi, P.C. Burger, M. Walker, R. Selker, N.A. Vick, K. Black, M. Sisti, S. Brem, G. Mohr, P. Muller, R. Morawetz, S.C. Schold, Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas, The Lancet 345 (1995) 1008-1012.
96. K.D. Judy, A. Olivi, K.G. Buahin, A. Domb, J.I. Epstew, O.M. Colvin, H. Brem, Controlled release of a cyclophosphamide derivative with polymers is effective against rat gliomas, J. Neurosurg. 82 (1995) 481-486.
97. K.A. Walter, M.A. Cahan, A. Gur, B. Tyler, J. Hilton, O.M. Colvin, P.C. Burger, A. Domb, H. Brem, Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma, Cancer Res. 54 (1994) 2207-2212.
98. J.D. Weingart, E.P. Sipos, H. Brem, The role of minocycline in the treatment of intracranial 9L glioma, J. Neurosurg. 82 (1995) 635-640.
99. Y. Tajika, Y. Muragaki, H. Hiyama, K. Takakura, M. Yoshida, M. Kumakura, Local chemotherapy with slowly-releasing anticancer drug polymers for malignant brain tumors, J. Control. Release 32 (1994) 1-8.
100. M. Libert, R.L. Wahl, G. Lawless, P.E. McKeever, J.A. Taren, W.H. Beierwaltes, R. Brassewell, Direct stereotactic intracerebral injection of monoclonal antibodies and their fragments: a potential approach to brain tumor immunotherapy, Am. J. Physiologic Imaging 5 (1990) 55-59.
101. P. Riva, A. Arista, V. Tison, C. Sturiale, G. Franceschi, A. Spinell, N. Riva, M. Casi, G. Moscatelli, M. Frattarelli, Intralesional radioimmunotherapy of malignant gliomas: an effective treatment in recurrent tumors, Cancer 73 (1994) 1076-1082.
102. S.C. Mehta, J.J. Olson, D.R. Lu, Brain tissue reaction following intracerebral injection of free or liposomally encapsulated BSH, Drug Del. 2 (1995) 175-180.
103. R.F. Barth, F. Alam, A.H. Soloway, D.M. Adams, Delivery of boron-10 for neutron capture therapy by means of polyclonal and monoclonal antibodies: progress and problems. In: H. Hatanaka (Ed.), Boron Neutron Capture Therapy for Tumors. Nishimura, Niigata, Japan, 1986, pp. 346-352.
104. F. Alam, R.F. Barth, A.H. Soloway, Boron containing immunoconjugates for neutron capture therapy of cancer and for immunocytochemistry, Antibody Immunoconjugates Radiopharma. 2 (1989) 145-163.
105. R.F. Barth, N. Mafune, F. Alam, D.M. Adams, A.H. Soloway, E. Makroglou, Conjugation, purification and characterization of boronated monoclonal antibodies for use in neutron capture therapy, Strahlenther. Onkol. 165 (1989) 142-145.
106. S. Novick, M. Quastel, S. Marcus, D. Chipman, G. Shani, R.F. Barth, A.H. Soloway, Binding of boronated polysine to immunoglobulin by way of glycoside moieties: Immunoreactivity and boron content. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy. Plenum, New York, 1993, pp. 357-360.
107. R.F. Barth, A.H. Soloway, D.M. Adams, F. Alam, Delivery of boron-10 for neutron capture therapy by means of monoclonal antibody: starburst dendrimer immunoconjugates. In: B. Allen, D. Moore and B. Harrington (Eds.), Progress in Neutron Capture Therapy for Cancer. Plenum, New York, 1992, pp. 265-268.
108. R.F. Barth, D.M. Adams, A.H. Soloway, F. Alam, M.V. Darby, Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy, Bioconjugate Chem. 5 (1994) 58-66.
109. R.F. Barth, D.M. Adams, A.H. Soloway, M. Darby, In vivo distribution of boronated monoclonal antibodies and starburst dendrimers. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy. Plenum, New York, 1993. pp. 351-355.
110. A. Varadarajan, M.F. Hawthorne, Novel carboranyl amino acids and peptides: reagents for antibody modification and subsequent neutron capture studies, Bioconjugate Chem. 2 (1991) 242-253.
111. M.F. Hawthorne, Boron delivery to tumors mediated by macromolecules and vesicles. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy. Plenum, New York, 1993, pp. 345-350.
112. R. Kane, C. Lee, C. Coe, M.S. Rose, K. Drechsel, M. Hawthorne, Novel carboranyl diols and their derived phosphate esters. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy. Plenum, New York, 1993, pp. 293-296.
113. S.H. Bigner, P.C. Burger, A.J. Wong, Gene amplification in malignant human gliomas: clinical and histopathologic aspects, J. Neuropathol. Exp. Neurol. 47 (1988) 191-205.
114. 10B to malignant gliomas. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy. Plenum, New York, 1993, pp. 371-375.
115. J. Capala, R.F. Barth, M. Lauzon, D.M. Adams, A.H. Soloway, R.A. Fenstermaker, J. Carlsson, Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors, Bioconjugate Chem. 7 (1996) 7-15.
116. E.A. Neuwelt, P.A. Barnett, K.E. Hellström, C.I. McCormick, F.L. Ramsey, Effect of blood-brain barrier disruption on intact and fragment monoclonal antibody localization in intracerebral human lung carcinoma xenografts, J. Nucl. Med. 35 (1994) 1831-1841.
117. E.A. Neuwelt, P.A. Barnett, K.E. Hellström, P. Beaumier, C.I. McCormick, R.M. Weigel, Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption, Cancer Res. 48 (1988) 4725-4729.
118. G. Gregoriadis, A.T. Florence, Liposomes in drug delivery: clinical, diagnostic and ophthalmic potential, Drugs 45(1) (1993) 15-28.
119. A. Gabizon, D.C. Price, J. Huberty, R.S. Bresalier, D. Papahadjopoulos, Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies, Cancer Res. 50 (1990) 6371-6378.
120. N.Z. Wu, D. Da, T.L. Rudoll, D. Needham, A.R. Whorton, M.W. Dewhirst, Increased microvascular permeability contributed to preferential accumulation of stealth liposomes in tumor tissue, Cancer Res. 53 (1993) 3765-3770.
121. K. Shelly, D.A. Feaks, M.F. Hawthorne, P.G. Schmidt, T.A. Kritsch, W.F. Bauer, Model studies directed toward the boron neutron capture therapy of cancer: Boron delivery to murine tumors with liposomes, Proc. Natl. Acad. Sci. USA 89 (1992) 9039-9043.
122. 3]: synthesis and liposomal delivery to murine tumors, Proc. Natl. Acad. Sci. USA 91 (1994) 3029-3033.
123. R. Grennuso, M.K. Spigelman, M. Chinol, R.A. Zappulla, J. Nieves, S. Vallabhajosula, P.A. Paciucci, S.T. Goldsmith, J.F. Holland, Effect of blood-brain barrier and blood-tumor barrier modification on central nervous system liposomal uptake, Cancer Invest. 11 (1993) 118-128.
124. M.J. Micklus, N.H. Greig, J. Tung, S.I. Rapoport, Targeting of liposomes to the blood-brain barrier in rats, Drug Del. 1 (1993) 21-26.
125. H. Yanagië, T. Tomita, H. Kobayashi, Y. Fujii, T. Takahashi, K. Hasumi, H. Nariuchi, M. Sekiguchi, Application of boronated anti-CEA immunoliposomes to tumor cell growth inhibition in in vitro boron neutron capture therapy model, Br. J. Cancer 63 (1991) 522-526.
126. L. Leserman, P. Machy, O. Zelphati, (1994) Immunoliposome-mediated delivery of nucleic acids: a review of our laboratory's experience, J. Liposome Res. 4(1) (1994) 107-119.
127. J. Yoshida, M. Mixuno, Simple preparation and characterization of cationic liposomes associated with monoclonal antibody against glioma-associated antigen (immunoliposomes), J. Liposome Res. 5(4) (1995) 981-995.
128. B.H. Laster, S.B. Kahl, E.A. Popenoe, D.W. Pate, R.G. Fairchild, Biological efficacy of boronated low-density lipoprotein for boron neutron capture therapy as measured in cell culture, Cancer Res. 51 (1991) 4588-4593.
129. S. Kahl, D. Pate, L. Wainschel, Low density lipoprotein reconstitutions with alkyl and aryl carboranes. In: A.H. Soloway, R.F. Barth and D.E. Carpenter (Eds.), Advances in Neutron Capture Therapy. Plenum, New York, 1993, pp. 399-402.
130. 99mTc-low-density lipoprotein in human malignant glioma, Br. J. Cancer 71 (1995) 383-387.
131. J. Kreuter, R.N. Alyyautidin, D.A. Kharkevich, A.A. Ivanov, Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles), Brain Res. 674 (1995) 171-174.